DK1439829T3 - Lægemiddel indeholdende 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol med forsinket frigivelse af det aktive stof - Google Patents

Lægemiddel indeholdende 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol med forsinket frigivelse af det aktive stof

Info

Publication number
DK1439829T3
DK1439829T3 DK02781278T DK02781278T DK1439829T3 DK 1439829 T3 DK1439829 T3 DK 1439829T3 DK 02781278 T DK02781278 T DK 02781278T DK 02781278 T DK02781278 T DK 02781278T DK 1439829 T3 DK1439829 T3 DK 1439829T3
Authority
DK
Denmark
Prior art keywords
dimethylamino
phenol
propyl
ethyl
methyl
Prior art date
Application number
DK02781278T
Other languages
Danish (da)
English (en)
Inventor
Iris Ziegler
Johannes Bartholomaeus
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26010444&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1439829(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE10152469A external-priority patent/DE10152469A1/de
Priority claimed from DE2002148309 external-priority patent/DE10248309A1/de
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Application granted granted Critical
Publication of DK1439829T3 publication Critical patent/DK1439829T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
DK02781278T 2001-10-24 2002-10-22 Lægemiddel indeholdende 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol med forsinket frigivelse af det aktive stof DK1439829T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10152469A DE10152469A1 (de) 2001-10-24 2001-10-24 3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)phenol enthaltendes Arzneimittel mit verzögerter Wirkstofffreisetzung
DE2002148309 DE10248309A1 (de) 2002-10-16 2002-10-16 3-(3- Dimethylamino-1-ethyl-2-methyl-propyl) phenol enthaltendes Arzeimittel mit verzögerter Wirkstofffreisetzung
PCT/EP2002/011809 WO2003035053A1 (de) 2001-10-24 2002-10-22 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol enthaltendes arzneimittel mit verzögerter wirkstofffreisetzung

Publications (1)

Publication Number Publication Date
DK1439829T3 true DK1439829T3 (da) 2005-10-10

Family

ID=26010444

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02781278T DK1439829T3 (da) 2001-10-24 2002-10-22 Lægemiddel indeholdende 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol med forsinket frigivelse af det aktive stof

Country Status (29)

Country Link
US (7) US20050058706A1 (ko)
EP (1) EP1439829B1 (ko)
JP (2) JP4758064B2 (ko)
KR (1) KR100958045B1 (ko)
CN (1) CN100402021C (ko)
AR (1) AR036943A1 (ko)
AT (1) ATE303802T1 (ko)
AU (1) AU2002349001C1 (ko)
BR (1) BRPI0213653B8 (ko)
CA (1) CA2464578C (ko)
CO (1) CO5570662A2 (ko)
CY (1) CY2012022I2 (ko)
DE (1) DE50204198D1 (ko)
DK (1) DK1439829T3 (ko)
EC (1) ECSP045102A (ko)
ES (1) ES2248622T3 (ko)
HK (1) HK1068539A1 (ko)
HU (1) HU230161B1 (ko)
IL (2) IL161587A0 (ko)
MX (1) MXPA04003742A (ko)
MY (1) MY127797A (ko)
NO (2) NO331896B1 (ko)
NZ (1) NZ532999A (ko)
PE (1) PE20030527A1 (ko)
PL (1) PL216535B1 (ko)
PT (1) PT1439829E (ko)
SI (1) SI1439829T1 (ko)
WO (2) WO2003035054A1 (ko)
ZA (1) ZA200403928B (ko)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
HUE033042T2 (en) 2002-11-22 2017-11-28 Gruenenthal Gmbh Combination of selected analgesics with COX II inhibitors
DE10361596A1 (de) * 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE10336400A1 (de) * 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102004020220A1 (de) * 2004-04-22 2005-11-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE102005005446A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
JP4939217B2 (ja) * 2003-08-06 2012-05-23 グリューネンタ−ル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 乱用防止剤形
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DK1612203T3 (da) * 2004-06-28 2007-12-03 Gruenenthal Gmbh Krystallinske former af (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenolhydrochlorid
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102004032103A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
CA2572352A1 (en) * 2004-07-01 2006-01-12 Gruenenthal Gmbh Oral dosage form safeguarded against abuse containing (1r,2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol
DE102005005449A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
EP2012763B1 (en) * 2006-04-28 2011-03-23 Grünenthal GmbH Pharmaceutical combination comprising 3- (3-dimethylamin0-1-ethyl-2-methyl-pr0pyl) -phenol and an nsaid
CN101431990B (zh) * 2006-04-28 2011-08-03 格吕伦塔尔有限公司 包含3-（3-二甲基氨基-1-乙基-2-甲基-丙基）-酚和对乙酰氨基酚的药物结合
CN101091725A (zh) * 2006-06-23 2007-12-26 天津天士力制药股份有限公司 一种中药颗粒及其制备方法
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
DE102007011485A1 (de) * 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
EP1985292A1 (en) * 2007-04-23 2008-10-29 Grünenthal GmbH Titration of tapentadol
DE102007019417A1 (de) * 2007-04-23 2008-11-13 Grünenthal GmbH Tapentadol zur Schmerzbehandlung bei Arthrose
MX2010005680A (es) * 2007-11-23 2010-12-21 Protect Pharmaceutical Corp Composiciones de tapentadol.
CN101939287B (zh) * 2007-12-07 2014-10-22 格吕伦塔尔有限公司 (1r,2r)-3-(3-二甲基氨基-1-乙基-2-甲基-丙基)-苯酚的结晶变体
WO2009092601A1 (en) 2008-01-25 2009-07-30 Grünenthal GmbH Pharmaceutical dosage form
MX2010012039A (es) 2008-05-09 2010-11-30 Gruenenthal Gmbh Proceso para la preparacion de una formulacion de polvo intermedia y una forma de dosificacion solida final bajo el uso de un paso de congelacion por rocio.
US20100190752A1 (en) * 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
PL2352494T3 (pl) 2008-10-30 2020-03-31 Grünenthal GmbH Nowe i silne postaci dawkowania tapentadolu
BR112012001547A2 (pt) 2009-07-22 2016-03-08 Gruenenthal Gmbh forma de dosagem farmacêutica extrusada por fusão a quente
RU2567723C2 (ru) 2009-07-22 2015-11-10 Грюненталь Гмбх Стабильная при окислении, прочная на излом лекарственная форма
ES2606227T3 (es) * 2010-02-03 2017-03-23 Grünenthal GmbH Preparación de una composición farmacéutica en polvo mediante una extrusora
WO2011124953A2 (en) * 2010-04-07 2011-10-13 Lupin Limited Controlled release pharmaceutical compositions of tapentadol
US20130116333A1 (en) * 2010-05-05 2013-05-09 Ratiopharm Gmbh Solid tapentadol in non-crystalline form
US8846765B2 (en) * 2010-06-15 2014-09-30 Gruenenthal Gmbh Pharmaceutical combination
RS55009B1 (sr) 2010-06-30 2016-11-30 Gruenenthal Gmbh Tapentadol za upotrebu u lečenju sindroma nervoznih creva
PT3650439T (pt) 2010-07-23 2021-03-03 Gruenenthal Gmbh Sais ou cocristais de 3-(3-dimetilamino-1-etil-2-metilpropil)fenol
PE20131126A1 (es) 2010-09-02 2013-10-21 Gruenenthal Chemie Forma de dosificacion resistente a alteracion que comprende un polimero anionico
RU2604676C2 (ru) 2010-09-02 2016-12-10 Грюненталь Гмбх Устойчивая к разрушению лекарственная форма, содержащая неорганическую соль
EP2680832B1 (en) 2011-03-04 2019-09-04 Grünenthal GmbH Aqueous pharmaceutical formulation of tapentadol for oral administration
EP2680834B1 (en) 2011-03-04 2017-10-18 Grünenthal GmbH Semisolid aqueous pharmaceutical composition containing tapentadol
CN107088226A (zh) 2011-03-04 2017-08-25 格吕伦塔尔有限公司 他喷他多的胃肠外给药
EP2694049B1 (en) 2011-04-05 2018-10-31 Grünenthal GmbH Tapentadol for preventing chronification of pain
JP6040219B2 (ja) 2011-04-05 2016-12-07 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 三叉神経因性痛に伴う疼痛の治療用タペンタドール
JP6014655B2 (ja) 2011-04-29 2016-10-25 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング うつ病および不安を予防し治療するためのタペンタドール
NO2736501T3 (ko) * 2011-07-29 2018-05-19
DK2736497T3 (da) 2011-07-29 2017-11-13 Gruenenthal Gmbh Stød-resistent tablet, der tilvejebringer en øjeblikkelig frigivelse af et lægemiddel.
CA2839123A1 (en) 2011-07-29 2013-02-07 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
EP2606879A1 (en) 2011-12-21 2013-06-26 Hexal AG Multiple unit pellet tablet formulation comprising an opioid
US20130225697A1 (en) 2012-02-28 2013-08-29 Grunenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
WO2013156453A1 (en) 2012-04-18 2013-10-24 Grünenthal GmbH Tamper resistant and dose-dumping resistant pharmaceutical dosage form
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
AR096438A1 (es) 2013-05-29 2015-12-30 Gruenenthal Gmbh Forma de dosificación resistente al uso indebido con perfil de liberación bimodal, proceso
CA2907950A1 (en) 2013-05-29 2014-12-04 Grunenthal Gmbh Tamper-resistant dosage form containing one or more particles
EP2808319A1 (en) 2013-05-31 2014-12-03 Arevipharma GmbH 3-[3-(Dimethylamino)-1-ethyl-2-methylpropyl]phenol resin complex
AU2014289187B2 (en) 2013-07-12 2019-07-11 Grunenthal Gmbh Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
EP2845625A1 (en) 2013-09-04 2015-03-11 Grünenthal GmbH Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome
WO2015071248A1 (en) 2013-11-15 2015-05-21 Synthon B.V. Abuse-proofed extended release pharmaceutical composition comprising tapentadol
MX371372B (es) 2013-11-26 2020-01-28 Gruenenthal Gmbh Preparacion de una composicion farmaceutica en polvo por medio de criomolienda.
EP2942054A1 (en) * 2014-05-09 2015-11-11 G.L. Pharma GmbH Slow-release pharmaceutical formulation
EP3142646A1 (en) 2014-05-12 2017-03-22 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
JP2017516789A (ja) 2014-05-26 2017-06-22 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング エタノール過量放出に対して防護されている多粒子
MX2017012312A (es) 2015-03-27 2018-01-18 Gruenenthal Gmbh Formulacion estable para administracion parenteral de tapentadol.
KR20170139158A (ko) 2015-04-24 2017-12-18 그뤼넨탈 게엠베하 즉시 방출되고 용매 추출 방지된 변조 방지된 투여 형태
CA2998259A1 (en) 2015-09-10 2017-03-16 Grunenthal Gmbh Protecting oral overdose with abuse deterrent immediate release formulations
EP3231420A1 (en) 2016-02-29 2017-10-18 G.L. Pharma GmbH Abuse-deterrent pharmaceutical compositions
KR20190057349A (ko) 2016-09-23 2019-05-28 그뤼넨탈 게엠베하 타펜타돌의 비경구 투여용 안정한 제제
WO2018153947A1 (en) 2017-02-23 2018-08-30 Grünenthal GmbH Tapentadol as local anesthetic
ES2963929T3 (es) * 2017-05-29 2024-04-03 Gruenenthal Gmbh Forma farmacéutica oral multipartículas que proporciona liberación prolongada de tapentadol
AU2020100442B4 (en) * 2020-03-02 2020-06-18 Grünenthal GmbH Dosage form providing prolonged release of tapentadol phosphoric acid salt
EP4003318A1 (en) 2020-03-02 2022-06-01 Grünenthal GmbH Dosage form providing prolonged release of tapentadol phosphoric acid salt
AU2020100441B4 (en) * 2020-03-02 2020-06-18 Grünenthal GmbH Dosage form providing prolonged release of tapentadol phosphoric acid salt
PL3875077T3 (pl) * 2020-03-02 2024-03-11 Grünenthal GmbH Postać dawkowania zapewniająca przedłużone uwalnianie soli kwasu fosforowego tapentadolu
EP3875080A1 (en) 2020-03-02 2021-09-08 Grünenthal GmbH Dosage form providing prolonged release of tapentadol phosphoric acid salt
BR112022018572A2 (pt) 2020-03-16 2022-11-01 Gruenenthal Gmbh Comprimido sulcado
DE202020104285U1 (de) 2020-07-24 2020-12-18 Grünenthal GmbH Ethylcellulose-beschichtete Partikel enthaltend ein Salz aus Tapentadol und Phosphorsäure
LT3995135T (lt) 2020-11-10 2022-08-25 Grünenthal GmbH Tapentadolio l-(+)-vyno rūgščių druskos pailginto atpalaidavimo
DE202020005470U1 (de) 2020-11-10 2022-01-25 Grünenthal GmbH Darreichungsformen mit verlängerter Freisetzung eines Salzes von Tapentadol mit L-(+)-Weinsäure
MX2023005472A (es) 2020-11-10 2023-05-22 Gruenenthal Gmbh Formas de dosificacion de liberacion sostenida de una sal de tapentadol con acido l-(+)-tartarico.

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870790A (en) * 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
DE2117239A1 (de) 1971-04-08 1972-11-16 König, Wilhelm, 4712 Werne Verfahren zum Erstellen von Wänden aus Schalungssteinen
US4126672A (en) * 1976-02-04 1978-11-21 Hoffmann-La Roche Inc. Sustained release pharmaceutical capsules
US4389393A (en) 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4443428A (en) * 1982-06-21 1984-04-17 Euroceltique, S.A. Extended action controlled release compositions
US5612183A (en) 1983-01-10 1997-03-18 Gen-Probe Incorporated Method for determining the effect of antimicrobial agents on growth using ribosomal nucleic acid subunit subsequence specific probes
US4765989A (en) * 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4612008A (en) * 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4783337A (en) * 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
GB8519310D0 (en) 1985-07-31 1985-09-04 Zyma Sa Granular active substances
GB8626098D0 (en) * 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5286493A (en) * 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
DK0661045T3 (da) * 1992-09-18 2002-10-28 Yamanouchi Pharma Co Ltd Hydrogelpræparat med forsinket frigivelse
NZ260408A (en) * 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
DE4329794C2 (de) 1993-09-03 1997-09-18 Gruenenthal Gmbh Tramadolsalz enthaltende Arzneimittel mit verzögerter Wirkstofffreisetzung
AU694463B2 (en) 1993-11-17 1998-07-23 Lequio Pharma Co. Ltd Composition for curing lesioned tissue, process for producing the same, and use thereof
US5891471A (en) * 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
US5843480A (en) * 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
DE4426245A1 (de) * 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
US5478572A (en) * 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form
CN1125572A (zh) * 1994-12-28 1996-07-03 顺德市广容制药厂 一种罗通定痛释片的制作方法
IL139728A (en) * 1995-01-09 2003-06-24 Penwest Pharmaceuticals Compan Aqueous slurry composition containing microcrystalline cellulose for preparing a pharmaceutical excipient
DE19525137C2 (de) 1995-07-11 2003-02-27 Gruenenthal Gmbh 6-Dimethylaminomethyl-1-phenyl-cyclohexanverbin -dungen als Zwischenprodukte zur Herstellung pharmazeutischer Wirkstoffe
DE19609847A1 (de) 1996-03-13 1997-09-18 Gruenenthal Gmbh Dimethyl-(3-aryl-but-3-enyl)-aminverbindungen als pharmazeutische Wirkstoffe
US6096339A (en) 1997-04-04 2000-08-01 Alza Corporation Dosage form, process of making and using same
US6093420A (en) * 1996-07-08 2000-07-25 Edward Mendell Co., Inc. Sustained release matrix for high-dose insoluble drugs
DE19630035A1 (de) * 1996-07-25 1998-01-29 Asta Medica Ag Tramadol Multiple Unit Formulierungen
JP4083818B2 (ja) * 1997-06-06 2008-04-30 ディポメド，インコーポレイティド 高度可溶性薬物の制御された放出のための胃滞留性の経口薬物投与形
US6245357B1 (en) * 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US6106862A (en) * 1998-08-13 2000-08-22 Andrx Corporation Once daily analgesic tablet
DE19901683B4 (de) 1999-01-18 2005-07-21 Grünenthal GmbH Analgetikum mit kontrollierter Wirkstofffreisetzung
MXPA02004293A (es) * 1999-10-29 2002-10-31 Euro Celtique Sa Formulaciones de hidrocodona de liberacion controlada..
DE10109763A1 (de) 2001-02-28 2002-09-05 Gruenenthal Gmbh Pharmazeutische Salze
DE10248309A1 (de) 2002-10-16 2004-04-29 Grünenthal GmbH 3-(3- Dimethylamino-1-ethyl-2-methyl-propyl) phenol enthaltendes Arzeimittel mit verzögerter Wirkstofffreisetzung

Also Published As

Publication number Publication date
MXPA04003742A (es) 2004-07-23
US20120034304A1 (en) 2012-02-09
US20160151309A1 (en) 2016-06-02
ZA200403928B (en) 2005-07-27
US20200038344A1 (en) 2020-02-06
ECSP045102A (es) 2004-06-28
WO2003035053A1 (de) 2003-05-01
NO20041924L (no) 2004-05-11
BR0213653A (pt) 2004-10-26
ATE303802T1 (de) 2005-09-15
CA2464578A1 (en) 2003-05-01
EP1439829B1 (de) 2005-09-07
IL161587A0 (en) 2004-09-27
NO2012007I1 (no) 2012-05-21
BRPI0213653B1 (pt) 2018-04-03
NZ532999A (en) 2007-06-29
JP2005506367A (ja) 2005-03-03
BRPI0213653B8 (pt) 2021-05-25
AU2002349001B2 (en) 2003-05-06
US20170087103A1 (en) 2017-03-30
MY127797A (en) 2006-12-29
ES2248622T3 (es) 2006-03-16
AR036943A1 (es) 2004-10-13
HUP0402104A2 (hu) 2005-03-29
JP2010280697A (ja) 2010-12-16
CO5570662A2 (es) 2005-10-31
AU2002349001C1 (en) 2022-04-14
PT1439829E (pt) 2005-11-30
HU230161B1 (en) 2015-09-28
CA2464578C (en) 2011-10-11
NO331896B1 (no) 2012-04-30
US11007156B2 (en) 2021-05-18
US20050058706A1 (en) 2005-03-17
WO2003035054A1 (de) 2003-05-01
NO2012007I2 (no) 2013-01-02
PL369756A1 (en) 2005-05-02
CN100402021C (zh) 2008-07-16
HK1068539A1 (en) 2005-04-29
US20130237608A1 (en) 2013-09-12
PL216535B1 (pl) 2014-04-30
CY2012022I1 (el) 2015-08-05
CY2012022I2 (el) 2015-08-05
PE20030527A1 (es) 2003-07-26
CN1607947A (zh) 2005-04-20
US20180221308A1 (en) 2018-08-09
KR100958045B1 (ko) 2010-05-17
IL161587A (en) 2009-12-24
EP1439829A1 (de) 2004-07-28
KR20040047964A (ko) 2004-06-05
DE50204198D1 (de) 2005-10-13
SI1439829T1 (sl) 2006-02-28
JP4758064B2 (ja) 2011-08-24

Similar Documents

Publication Publication Date Title
DK1439829T3 (da) Lægemiddel indeholdende 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol med forsinket frigivelse af det aktive stof
DK1501485T3 (da) Tablet med höjt indhold af aktivt stof
AU2002349001A1 (en) Pharmaceutical containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol and providing delayed release of the active ingredient
DK1542660T3 (da) Administration af langvarig frigørelse af amfetaminsalte
DK1020185T3 (da) Opioide analgetika med kontrolleret frigivelse af aktivt stoft
DK1451143T3 (da) Fremgangsmåder til fremstilling af O-desmethylvenlafaxin
PT1207867E (pt) Formas de administracao farmaceuticas orais retardadas contendo tramadol
DK1148871T3 (da) Gliclazidholdig matrixtablet med forsinket frisætning af aktivt stof efter oral administrering
DK1297825T3 (da) Faste orale dosisformer af simethicon
DE602005016551D1 (de) Stabilisierte supergesättigte feste lösungen von steroidalen arzneimitteln
NO20034419L (no) Antifungalt preparat med forbedret biotilgjengelighet
DK1121112T3 (da) Lagringsdygtigt koncentrat af aktivt stof med formoterol
DK1671661T3 (da) Antibiotikum/antibiotika indeholdende knogleerstatningsmateriale med forsinket frigivelse af det aktive stof
DK1795186T3 (da) Flupirtinomfattende lægemiddelformulering med en kontrolleret frisætning af det aktive middel
DE60206835D1 (de) Thermisch gesteuerter Entriegelungsmechanismus
DK1401451T3 (da) Quinazolinderivater, der fremmer frigivelsen af parathyroidhormon
NO20044132L (no) Legemidler som inneholder aktive ingredienser som senker kolesterolnivaet med tidsforsinket frigjoring av det aktive middelet
DK1475379T3 (da) Anvendelse af scopinesterderivater til fremstilling af lægemidler
DK1455760T3 (da) Orla fludara - reneste formulering med hurtig frigörelse af aktivstoffet
DE50202530D1 (de) Release-Folie
NO20040205L (no) Farmasøytiske preparater inneholdende ionebytterharpikser belagt med virksomt stoff
DK1385512T3 (da) Anvendelse af pyridoindolonderivater til fremstilling af anticancerlægemidler
EE200300045A (et) Kristalne ravimaine
ITMI20011457A0 (it) Composizione farmaceutica a rilascio modificato contenente bupropionehc1 come sostanza attiva
DK1496904T3 (da) Anvendelse af lægemidler indeholdende N,N'-disubstituerede piperazinforbindelser